Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Moodys
McKesson
Express Scripts
McKinsey

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Patent: 7,435,750

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,435,750
Title:Method of using substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
Abstract: The present invention is directed to substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I: ##STR00001## wherein Ar.sub.1, Ar.sub.3, A, B and D are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
Inventor(s): Cai; Sui Xiong (San Diego, CA), Zhang; Han-Zhong (San Diego, CA), Drewe; John A. (Carlsbad, CA), Reddy; P. Sanjeeva (San Diego, CA), Kasibhatla; Shailaja (San Diego, CA), Kuemmerle; Jared Daniel (Del Mar, CA), Ollis; Kristin P. (San Diego, CA)
Assignee: Cytovia, Inc. (San Diego, CA)
Application Number:11/074,077
Patent Claims:see list of patent claims

Details for Patent 7,435,750

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Cytovia, Inc. (San Diego, CA) 2039-03-29 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Cytovia, Inc. (San Diego, CA) 2039-03-29 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Cytovia, Inc. (San Diego, CA) 2039-03-29 RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Start Trial Cytovia, Inc. (San Diego, CA) 2039-03-29 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07   Start Trial Cytovia, Inc. (San Diego, CA) 2039-03-29 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Cytovia, Inc. (San Diego, CA) 2039-03-29 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Cytovia, Inc. (San Diego, CA) 2039-03-29 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 7,435,750

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Express Scripts
McKinsey
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.